These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 11260083)
1. Cyclin D1 and E2F-1 immunoreactivity in bone marrow biopsy specimens of multiple myeloma: relationship to proliferative activity, cytogenetic abnormalities and DNA ploidy. Wilson CS; Butch AW; Lai R; Medeiros LJ; Sawyer JR; Barlogie B; McCourty A; Kelly K; Brynes RK Br J Haematol; 2001 Mar; 112(3):776-82. PubMed ID: 11260083 [TBL] [Abstract][Full Text] [Related]
2. Expression of the cell-cycle-related proteins E2F-1, p53, mdm-2, p21waf-1, and Ki-67 in multiple myeloma: correlation with cyclin-D1 immunoreactivity. Lai R; Medeiros LJ; Wilson CS; Sun NC; Koo C; McCourty A; Brynes RK Mod Pathol; 1998 Jul; 11(7):642-7. PubMed ID: 9688185 [TBL] [Abstract][Full Text] [Related]
3. The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. Hoyer JD; Hanson CA; Fonseca R; Greipp PR; Dewald GW; Kurtin PJ Am J Clin Pathol; 2000 Jun; 113(6):831-7. PubMed ID: 10874884 [TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14). Pruneri G; Fabris S; Baldini L; Carboni N; Zagano S; Colombi MA; Ciceri G; Lombardi L; Rocchi M; Buffa R; Maiolo AT; Neri A Am J Pathol; 2000 May; 156(5):1505-13. PubMed ID: 10793062 [TBL] [Abstract][Full Text] [Related]
5. Cell cycle analysis and expression of cell cycle regulator genes in myeloma cells overexpressing cyclin D1. Yata K; Sadahira Y; Otsuki T; Sakaguchi H; Isozaki Y; Uno M; Kurebayashi J; Fujii T; Eda S; Ueki A; Yawata Y; Yamada O; Sugihara T Br J Haematol; 2001 Sep; 114(3):591-9. PubMed ID: 11552984 [TBL] [Abstract][Full Text] [Related]
6. Frequency and distribution of trisomy 11 in multiple myeloma patients: relation with overexpression of CCND1 and t(11;14). Guglielmelli T; Giugliano E; Cappia S; Papotti M; Saglio G Cancer Genet Cytogenet; 2007 Feb; 173(1):51-6. PubMed ID: 17284370 [TBL] [Abstract][Full Text] [Related]
7. Cyclin D1 expression in patients with multiple myeloma. Troussard X; Avet-Loiseau H; Macro M; Mellerin MP; Malet M; Roussel M; Sola B Hematol J; 2000; 1(3):181-5. PubMed ID: 11920187 [TBL] [Abstract][Full Text] [Related]
8. Roles of E2F1 in mesangial cell proliferation in vitro. Inoshita S; Terada Y; Nakashima O; Kuwahara M; Sasaki S; Marumo F Kidney Int; 1999 Dec; 56(6):2085-95. PubMed ID: 10594784 [TBL] [Abstract][Full Text] [Related]
9. Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression. Hiyama H; Iavarone A; LaBaer J; Reeves SA Oncogene; 1997 May; 14(21):2533-42. PubMed ID: 9191053 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of the cyclin D1/E2F pathway by PCA-4230, a potent repressor of cellular proliferation. Goukassian D; Sanz-González SM; Pérez-Roger I; Font de Mora J; Ureña J; Andrés V Br J Pharmacol; 2001 Apr; 132(7):1597-605. PubMed ID: 11264255 [TBL] [Abstract][Full Text] [Related]
11. Overexpression of D-type cyclins, E2F-1, SV40 large T antigen and HPV16 E7 rescue cell cycle arrest of tsBN462 cells caused by the CCG1/TAF(II)250 mutation. Sekiguchi T; Nishimoto T; Hunter T Oncogene; 1999 Mar; 18(10):1797-806. PubMed ID: 10086334 [TBL] [Abstract][Full Text] [Related]
12. Rb and E2F-1 regulate telomerase activity in human cancer cells. Crowe DL; Nguyen DC Biochim Biophys Acta; 2001 Mar; 1518(1-2):1-6. PubMed ID: 11267653 [TBL] [Abstract][Full Text] [Related]
13. Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels. Specht K; Haralambieva E; Bink K; Kremer M; Mandl-Weber S; Koch I; Tomer R; Hofler H; Schuuring E; Kluin PM; Fend F; Quintanilla-Martinez L Blood; 2004 Aug; 104(4):1120-6. PubMed ID: 15090460 [TBL] [Abstract][Full Text] [Related]
14. Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells. Katayama Y; Sakai A; Okikawa Y; Oue N; Asaoku H; Sasaki A; Imanaka F; Tsujimoto T; Takimoto Y; Masuda R; Nakaju N; Otsuki T; Yasui W; Kimura A Int J Oncol; 2004 Sep; 25(3):579-95. PubMed ID: 15289859 [TBL] [Abstract][Full Text] [Related]
15. Activation of the E2F transcription factor by cyclin D1 is blocked by p16INK4, the product of the putative tumor suppressor gene MTS1. Schulze A; Zerfass K; Spitkovsky D; Henglein B; Jansen-Dürr P Oncogene; 1994 Dec; 9(12):3475-82. PubMed ID: 7970707 [TBL] [Abstract][Full Text] [Related]
16. A new multiple myeloma cell line, MEF-1, possesses cyclin D1 overexpression and the p53 mutation. Yufu Y; Goto T; Choi I; Uike N; Kozuru M; Ohshima K; Taniguchi T; Motokura T; Yatabe Y; Nakamura S Cancer; 1999 Apr; 85(8):1750-7. PubMed ID: 10223569 [TBL] [Abstract][Full Text] [Related]
17. Regulation of E2F-1 gene expression by p130 (Rb2) and D-type cyclin kinase activity. Johnson DG Oncogene; 1995 Nov; 11(9):1685-92. PubMed ID: 7478595 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of cyclin D1 and p53 in multiple myeloma: relationship to proliferative activity and prognostic significance. Markovic O; Marisavljevic D; Cemerikic V; Suvajdzic N; Milic N; Colovic M Med Oncol; 2004; 21(1):73-80. PubMed ID: 15034217 [TBL] [Abstract][Full Text] [Related]
19. E2F-1: a proliferative marker of breast neoplasia. Zhang SY; Liu SC; Al-Saleem LF; Holloran D; Babb J; Guo X; Klein-Szanto AJ Cancer Epidemiol Biomarkers Prev; 2000 Apr; 9(4):395-401. PubMed ID: 10794484 [TBL] [Abstract][Full Text] [Related]